Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 5/2011

01-10-2011 | SHORT REPORT

Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib

Authors: Romain Coriat, Stanislas Ropert, Olivier Mir, Bertrand Billemont, Stanislas Chaussade, Pierre-Philippe Massault, Benoit Blanchet, Olivier Vignaux, François Goldwasser

Published in: Investigational New Drugs | Issue 5/2011

Login to get access

Summary

Recently, pneumatosis intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on pneumatosis intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to pneumatosis intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that pneumatosis intestinalis is a probable class-effect of anti-VEGF agents.
Literature
1.
Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109PubMedCrossRef
2.
Atkins M, Jones CA, Kirkpatrick P (2006) Sunitinib maleate. Nat Rev 5:279–280CrossRef
3.
Asmis TR, Chung KY, Teitcher JB, Kelsen DP, Shah MA (2008) Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs 26:95–96PubMedCrossRef
4.
Heng Y, Schuffler MD, Haggitt RC, Rohrmann CA (1995) Pneumatosis intestinalis: a review. Am J Gastroenterol 90:1747–1758PubMed
5.
Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25–35PubMedCrossRef
6.
Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965–972PubMedCrossRef
7.
Steeghs N, Rabelink TJ, Op’t Roodt J, et al (2009) Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann Oncol
8.
Saif MW, Elfiky A, Salem RR (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14:1860–1869PubMedCrossRef
9.
Lordick F, Geinitz H, Theisen J, Sendler A, Sarbia M (2006) Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 64:1295–1298PubMedCrossRef
10.
Greenstein AJ, Nguyen SQ, Berlin A et al (2007) Pneumatosis intestinalis in adults: management, surgical indications, and risk factors for mortality. J Gastrointest Surg 11:1268–1274PubMedCrossRef
11.
St Peter SD, Abbas MA, Kelly KA (2003) The spectrum of pneumatosis intestinalis. Arch Surg 138:68–75PubMedCrossRef
12.
Ho LM, Paulson EK, Thompson WM (2007) Pneumatosis intestinalis in the adult: benign to life-threatening causes. Ajr 188:1604–1613PubMedCrossRef
13.
Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989PubMedCrossRef
14.
Mir O, Mouthon L, Alexandre J et al (2007) Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst 99:85–86PubMedCrossRef
15.
Loriot Y, Perlemuter G, Malka D et al (2008) Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clinical Practice 5:268–278
16.
Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10:559–568PubMedCrossRef
17.
Flaig TW, Kim FJ, La Rosa FG et al (2009) Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs 27:83–87PubMedCrossRef
18.
Mancuso MR, Davis R, Norberg SM et al (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610–2621PubMedCrossRef
19.
Cacheux W, Boisserie T, Staudacher L et al (2008) Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol 19:1659–1661PubMedCrossRef
20.
Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245PubMedCrossRef
Metadata
Title
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib
Authors
Romain Coriat
Stanislas Ropert
Olivier Mir
Bertrand Billemont
Stanislas Chaussade
Pierre-Philippe Massault
Benoit Blanchet
Olivier Vignaux
François Goldwasser
Publication date
01-10-2011
Publisher
Springer US
Published in
Investigational New Drugs / Issue 5/2011
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-010-9458-7

Other articles of this Issue 5/2011

Investigational New Drugs 5/2011 Go to the issue

PHASE II STUDIES

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Erratum

Erratum to: Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs

PHASE I STUDIES

Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer

PRECLINICAL STUDIES

A novel activity from an old compound: Manzamine A reduces the metastatic potential of AsPC-1 pancreatic cancer cells and sensitizes them to TRAIL-induced apoptosis

Preclinical Studies

An in vitro comparative study with furyl-1,4-quinones endowed with anticancer activities

PHASE I STUDIES

Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits